Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with chronic HBV；~* Receiving anti-HB viral therapy；~* 10 IU/ml≤HBsAg≤3000 IU/ml.~Exclusion Criteria:~* Patients co-infected with hepatitis C virus, HIV, HAV, HDV, HEV;~* Liver cirrhosis;~* Hepatocellular carcinoma;~* Autoimmune liver disease;~* Clinical hepatic decompensation;~* Fibroscan\>12 kPa;~* a. hemoglobin\<110g/L（female）\<120 g/L（male），platelet\<ULN，white blood cell\<2.5×109/L；b. bilirubin\>1.5 ×ULN，ALT\>2 × ULN，serum albumin\<35 g/L；c. INR\>1.5；d. serum creatinine \>1.5×ULN.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- lowest dose treatment group (Type: EXPERIMENTAL): Subjects will receive one single lowest dose of STSG-0002 Injection following protocol requirements
- low dose treatment group (Type: EXPERIMENTAL): Subjects will receive one single low dose of STSG-0002 Injection following protocol requirements
- Intermediate dose treatment group (Type: EXPERIMENTAL): Subjects will receive one single intermediate dose of STSG-0002 Injection following protocol requirements
- A single high dose of treatment group (Type: EXPERIMENTAL): Subjects will receive one single high dose of STSG-0002 Injection following protocol requirements

Based on this trial design, predict the completion outcome and termination type (if applicable).